VistaGen Therapeutics Stock Forecast, Price & News

VistaGen Therapeutics (NASDAQ:VTGN) Frequently Asked Questions

Is VistaGen Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VistaGen Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VistaGen Therapeutics stock.
View analyst ratings for VistaGen Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than VistaGen Therapeutics?

Wall Street analysts have given VistaGen Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but VistaGen Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting VistaGen Therapeutics?

VistaGen Therapeutics saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 12,080,000 shares, an increase of 29.5% from the September 15th total of 9,330,000 shares. Based on an average trading volume of 1,090,000 shares, the days-to-cover ratio is currently 11.1 days. Currently, 8.3% of the company's stock are sold short.
View VistaGen Therapeutics' Short Interest.

When is VistaGen Therapeutics' next earnings date?

VistaGen Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for VistaGen Therapeutics.

How were VistaGen Therapeutics' earnings last quarter?

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) posted its earnings results on Thursday, August, 12th. The company reported ($0.04) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.05) by $0.01. The business had revenue of $0.35 million for the quarter, compared to the consensus estimate of $0.37 million. VistaGen Therapeutics had a negative trailing twelve-month return on equity of 32.73% and a negative net margin of 1,561.84%.
View VistaGen Therapeutics' earnings history.

How has VistaGen Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

VistaGen Therapeutics' stock was trading at $0.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VTGN stock has increased by 360.0% and is now trading at $2.30.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for VTGN?

3 Wall Street analysts have issued 12 month price objectives for VistaGen Therapeutics' shares. Their forecasts range from $5.00 to $9.00. On average, they anticipate VistaGen Therapeutics' share price to reach $6.67 in the next twelve months. This suggests a possible upside of 189.9% from the stock's current price.
View analysts' price targets for VistaGen Therapeutics or view top-rated stocks among Wall Street analysts.

Who are VistaGen Therapeutics' key executives?

VistaGen Therapeutics' management team includes the following people:

• Shawn K. Singh, Chief Executive Officer & Director
• H. Ralph Snodgrass, President & Chief Scientific Officer
• Jerrold D. Dotson, Chief Financial Officer, Secretary & VP
• Mark A. Smith, Chief Medical Officer
• Ellis Wilson, Vice President-Global Clinical Operations

Who are some of VistaGen Therapeutics' key competitors?

Some companies that are related to VistaGen Therapeutics include Dicerna Pharmaceuticals (DRNA), Amneal Pharmaceuticals (AMRX), Kadmon (KDMN), Travere Therapeutics (TVTX), MorphoSys (MOR), COMPASS Pathways (CMPS), IGM Biosciences (IGMS), Supernus Pharmaceuticals (SUPN), Protagonist Therapeutics (PTGX), Enanta Pharmaceuticals (ENTA), Day One Biopharmaceuticals (DAWN), Axsome Therapeutics (AXSM), NGM Biopharmaceuticals (NGM), Centessa Pharmaceuticals (CNTA) and Zealand Pharma A/S (ZEAL).
View all of VTGN's competitors.

What other stocks do shareholders of VistaGen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other VistaGen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Advaxis (ADXS), Matinas BioPharma (MTNB), Rite Aid (RAD), Sorrento Therapeutics (SRNE), Lithium Americas (LAC), ImmunoGen (IMGN), Yamana Gold (AUY) and CRISPR Therapeutics (CRSP).

What is VistaGen Therapeutics' stock symbol?

VistaGen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."

Who are VistaGen Therapeutics' major shareholders?

VistaGen Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Epiq Partners LLC (0.47%) and Genesee Capital Advisors LLC (0.01%). Company insiders that own VistaGen Therapeutics stock include H Ralph Snodgrass and Jerrold Duane Dotson.
View institutional ownership trends for VistaGen Therapeutics.

Which institutional investors are selling VistaGen Therapeutics stock?

VTGN stock was sold by a variety of institutional investors in the last quarter, including Epiq Partners LLC.
View insider buying and selling activity for VistaGen Therapeutics or view top insider-selling stocks.

Which institutional investors are buying VistaGen Therapeutics stock?

VTGN stock was purchased by a variety of institutional investors in the last quarter, including Genesee Capital Advisors LLC.
View insider buying and selling activity for VistaGen Therapeutics or or view top insider-buying stocks.

How do I buy shares of VistaGen Therapeutics?

Shares of VTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VistaGen Therapeutics' stock price today?

One share of VTGN stock can currently be purchased for approximately $2.30.

How much money does VistaGen Therapeutics make?

VistaGen Therapeutics has a market capitalization of $443.68 million and generates $1.09 million in revenue each year. The company earns $-17.93 million in net income (profit) each year or ($0.49) on an earnings per share basis.

How many employees does VistaGen Therapeutics have?

VistaGen Therapeutics employs 21 workers across the globe.

What is VistaGen Therapeutics' official website?

The official website for VistaGen Therapeutics is www.vistagen.com.

Where are VistaGen Therapeutics' headquarters?

VistaGen Therapeutics is headquartered at 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080.

How can I contact VistaGen Therapeutics?

VistaGen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 577-3600 or via email at [email protected].